Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

504 questions · 511 findings · 66 reviews

No studies found 104 · 20.4%GRADE not reported 26 · 5.1%Very low 107 · 20.9%Low 129 · 25.2%Moderate 107 · 20.9%High 38 · 7.4%

100 mg olorinab 3 times/day vs 25 mg olorinab 3 times/day

At least 30% reduction in pain · people with Crohn's disease

It is very uncertain whether 100 mg olorinab 3 times/day changes pain intensity (30% reduction in weekly AAPS) compared with 25 mg olorinab 3 times/day (very low certainty).

1 finding from 1 review

Donepezil 10 mg/day vs donepezil 5 mg/day

Clinician‐rated global impression test (improved compared with baseline assessed using CIBIC‐plus at 24 weeks) · people with Alzheimer's disease

Donepezil 10 mg/day showed no clear difference in clinician‐rated global impression test (improved compared with… compared with donepezil 5 mg/day (moderate certainty).

1 finding from 1 review

Donepezil 10 mg/day vs donepezil 5 mg/day

Secondary outcome: acceptability of treatment · people with Alzheimer's disease

Donepezil 10 mg/day probably leads to higher acceptability of treatment (as measured by withdrawals from trial… compared with donepezil 5 mg/day (moderate certainty).

1 finding from 1 review

Donepezil 10 mg/day vs donepezil 5 mg/day

Risk for at least one adverse event per patient · people with Alzheimer's disease

Donepezil 10 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 24 weeks) compared with donepezil 5 mg/day (moderate certainty).

1 finding from 1 review

Topical NSAID (ketoprofen lysinate mouthwash, 160 mg) vs Topical NSAID (benzidamine hydrochloride mouthwash, 22.5 mg)

Failure to complete orthodontic treatment due to pain · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)

The review found no eligible studies for this question.

1 finding from 1 review

Topical NSAID (ketoprofen lysinate mouthwash, 160 mg) vs Topical NSAID (benzidamine hydrochloride mouthwash, 22.5 mg)

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)
1 finding from 1 review

Sugammadex 2.0 mg/kg vs neostigmine (any dose)

Risk of adverse events and serious adverse eventsb, bradycardia, PONV, and signs of residual neuromuscular blockade · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs

The review found no eligible studies for this question.

1 finding from 1 review